ResearchA curated selection of insights from the Maven Bio team.
An analysis of how major pharmaceutical companies rebalanced revenue across therapeutic areas between 2019 and 2024, highlighting oncology concentration, portfolio diversification, and the commercial impact of M&A and new blockbusters.
An analysis of the current clinical-stage landscape for KRAS-targeted therapies, examining the divergence between KRAS G12D–selective programs and pan-KRAS approaches, development maturity, and emerging tumor-specific strategies in pancreatic cancer.
A research report analyzing the launch velocity of new molecular entities (NMEs) and biologic entities (NBEs) across major pharmaceutical companies from 2021 to 2025.
In 2025, the FDA approved 46 new drugs across oncology, immunology, neurology, and rare diseases. This report examines key approval trends, mechanisms, and therapeutic focus areas shaping biopharma strategy.
An analysis of the largest pharma and biotech M&A deals of 2025, examining how Big Pharma deployed capital toward late-stage assets, platform technologies, and durable therapeutic franchises amid rising development costs and approaching patent expiries.
A comparative overview of capital efficiency metrics within the Chinese and US biotechnology sectors, focusing on the relationship between equity financing and upfront licensing structures.
A structured review of U.S. pharma manufacturing and R&D site investments announced in 2025, highlighting where capital was deployed, which companies announced site level expansions or new builds, and how these moves reinforce long term U.S. supply strategies.
Immunology remains the second-largest revenue category in global pharma, with multiple franchises now operating at a scale comparable to Humira at its peak. This report reviews the top-selling immunology drugs in Q3 2025, highlighting how indication expansion, portfolio transitions, and lifecycle management are reshaping competitive dynamics.
An analysis of disease-modifying therapies in type 1 diabetes, covering approved agents and late-stage pipeline programs across immunotherapy, cell therapy, and gene-based approaches reshaping treatment beyond insulin.
